Janssen's Stelara Demonstrated Sustained Efficiency In Improving Clinical Remission Rates In Chron's Patients Throughout Three Years; Safety Events Were Not Higher Amongst All Ustekinumab-Treated Patients Entering Long-Term Extension Study vs Placebo